Phencyclidine-induced Cognitive Impairments

苯环己哌啶引起的认知障碍

• 批准号: 6936109
• 负责人: Alan Lars Pehrson
• 金额: $ 2.78万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6936109
• 关键词: NMDA receptors; behavior test; behavioral /social science research tag; cognition disorders; disease /disorder etiology; disease /disorder model; drug adverse effect; drug screening /evaluation; frontal lobe /cortex; genetically modified animals; haloperidol; hippocampus; immunocytochemistry; laboratory mouse; memory disorders; model design /development; neurophysiology; nonhuman therapy evaluation; phencyclidine; predoctoral investigator; receptor expression; schizophrenia; substance abuse related disorder; western blottings

DESCRIPTION (provided by applicant): Despite major advances in treatment of schizophrenia, cognitive impairments are, in fact, the, most important determination of functional outcome. Rates of patient recovery in areas of social and vocational function remain at levels similar to those seen in the 1930s in spite of more effective antipsychotic drugs, thus, cognitive deficits are a major limiting factor, in recovery from schizophrenia, but little is known about the etiology of these deficits. It is important to develop a preclinical model to elucidate the molecular basis of these deficits and to screen drugs capable of treating these deficits. One approach for investigating the molecular correlates of behavior and drug action is the use of gene-targeted-knockout and transgenic animals. This technique allows for the manipulation of receptors for which selective pharmacological agents do not exist. Because these mutations are only available in mice, it is necessary to first develop preclinical assays using mice in order to use these techniques. The current proposal is an important first step in this process. C57BL/6-mice will be subchronically administered phencyclidine, which produces schizophrenia-like cognitive deficits in chronic abusers. The mice will be evaluated in a spatial memory task, and, changes in the expression of glutamate NMDA, NR1, and NR2 subunits will be assessed. The ability of the atypical antipsychotic olanzapine to attenuate PCP's behavioral effects and PCP's effects on expression of NMDA receptors in frontal cortex and hippocampus will then be assessed.

描述（由申请人提供）：尽管精神分裂症的治疗取得了重大进展，但认知障碍实际上是功能结果的最重要决定因素。尽管有更有效的抗精神病药物，但患者在社会和职业功能领域的康复率仍保持在与 20 世纪 30 年代相似的水平，因此，认知缺陷是精神分裂症康复的主要限制因素，但人们对这些缺陷的病因知之甚少。开发临床前模型来阐明这些缺陷的分子基础并筛选能够治疗这些缺陷的药物非常重要。 研究行为和药物作用的分子相关性的一种方法是使用基因靶向敲除和转基因动物。该技术允许操纵不存在选择性药物的受体。由于这些突变仅在小鼠中存在，因此有必要首先使用小鼠开发临床前检测才能使用这些技术。 当前的提案是这一过程中重要的第一步。 C57BL/6-小鼠将亚长期服用苯环己哌啶，这会在长期滥用者中产生类似精神分裂症的认知缺陷。 将在空间记忆任务中对小鼠进行评估，并评估谷氨酸 NMDA、NR1 和 NR2 亚基表达的变化。然后将评估非典型抗精神病药物奥氮平减弱 PCP 行为影响的能力以及 PCP 对额叶皮层和海马 NMDA 受体表达的影响。